Blood Advances

Clofarabine treatment of KMT2Ar infantile patients with acute lymphoblastic leukemia in St. Jude Total Therapy Study 16..  6:6131-6134. 2022

Erratum: Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma (Blood Adv. (2022) 6:14 (4122-4131) DOI: 10.1182/bloodadvances.2022007247).  6:6039. 2022

Pharmacokinetics, pharmacodynamics, safety and efficacy of crizanlizumab in patients with sickle cell disease. 2022

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML.  6:5570-5581. 2022

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years. 2022

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia.  6:4085-4092. 2022

Evaluating real-world treatment patterns and outcomes of mantle cell lymphoma.  6:4122-4131. 2022

Neighborhood disadvantage, health status, and healthcare utilization after blood or marrow transplant: BMTSS report. 2022

Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern.  6:3678-3683. 2022

Conditioning intensity and probability of live birth after blood or marrow transplantation, a BMTSS report.  6:2471-2479. 2022

Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.  6:1371-1380. 2022

Deferiprone vs deferoxamine for transfusional iron overload in SCD and other anemias: a randomized, open-label noninferiority study.  6:1243-1254. 2022

GRNDaD: big data and sickle cell disease..  6:1088. 2022

The ASH-ASPHO Choosing Wisely Campaign: 5 hematologic tests and treatments to question.  6:679-685. 2022

VpreB surrogate light chain expression in B-lineage ALL: A report from the Children's Oncology Group.  6:585-589. 2022

Restriction of HIV-1 infection in sickle cell trait.  5:4922-4934. 2021

Transcription factor MEF2D is required for the maintenance of MLL-rearranged acute myeloid leukemia.  5:4727-4740. 2021

Late-occurring venous thromboembolism in allogeneic blood or marrow transplant survivors: A BMTSS-HiGHS2 risk model.  5:4102-4111. 2021

Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma.  5:3748-3759. 2021

American Society of Hematology 2021 guidelines for sickle cell disease: Stem cell transplantation.  5:3668-3689. 2021

B-cell acute lymphoblastic leukemia in patients with germline RUNX1 mutations.  5:3199-3202. 2021

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance).  5:2775-2787. 2021

Gene expression signature predicts relapse in adult patients with cytogenetically normal acute myeloid leukemia.  5:1474-1482. 2021

Daratumumab plus RVd for newly diagnosed multiple myeloma: Final analysis of the safety run-in cohort of GRIFFIN.  5:1092-1096. 2021

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia.  5:504-512. 2021

Acute erythroid leukemia is enriched in NUP98 fusions: A report from the Children's Oncology Group.  4:6000-6008. 2020

Elevated plasma levels of syndecan-1 and soluble thrombomodulin predict adverse outcomes in thrombotic thrombocytopenic purpura.  4:5378-5388. 2020

Systems-based hematology: Highlighting successes and next steps.  4:4574-4583. 2020

Building access to care in adult sickle cell disease: Defining models of care, essential components, and economic aspects.  4:3804-3813. 2020

American society of hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults.  4:3528-3549. 2020

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.  4:2245-2253. 2020

Clinical outcomes of older patients with AML receiving hypomethylating agents: A large population-based study in the United States.  4:2192-2201. 2020

Myelodysplastic syndrome unrelated to lentiviral vector in a patient treated with gene therapy for sickle cell disease.  4:2058-2063. 2020

A phase 2 study of ATRA, arsenic trioxide, and gemtuzumab ozogamicin in patients with high-risk APL (SWOG 0535).  4:1683-1689. 2020

Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States.  4:1615-1623. 2020

Thrombotic, inflammatory, and HIF-regulated genes and thrombosis risk in polycythemia vera and essential thrombocythemia.  4:1115-1130. 2020

Clinical and functional significance of circular RNAs in cytogenetically normal AML.  4:239-251. 2020

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics.  4:253-262. 2020

Sex differences in the trajectory of glomerular filtration rate in pediatric and murine sickle cell anemia.  4:263-265. 2020

Longitudinal assessments of plasma ADAMTS13 biomarkers predict recurrence of immune thrombotic thrombocytopenic purpura.  3:4177-4186. 2019

Smooth muscle cytochrome b5 reductase 3 deficiency accelerates pulmonary hypertension development in sickle cell mice.  3:4104-4116. 2019

American Society of Hematology 2019 guidelines for sickle cell disease: Cardiopulmonary and kidney disease.  3:3867-3897. 2019

End points for sickle cell disease clinical trials: Renal and cardiopulmonary, cure, and low-resource settings.  3:4002-4020. 2019

Hyperfiltration predicts long-term renal outcomes in humanized sickle cell mice.  3:1460-1475. 2019

Phase 1b study of the MDM2 inhibitor AMG 232 with or without trametinib in relapsed/refractory acute myeloid leukemia.  3:1939-1949. 2019

Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1.  2:2829-2836. 2018

The impact of phlebotomy and hydroxyurea on survival and risk of thrombosis among older patients with polycythemia vera.  2:2681-2690. 2018

Double-blind, randomized, multicenter phase 2 study of SC411 in children with sickle cell disease (SCOT trial).  2:1969-1979. 2018

Platelet transfusions improve hemostasis and survival in a substudy of the prospective, randomized PROPPR trial.  2:1696-1704. 2018

Ten-year outcome of patients with acute myeloid leukemia not treated with allogeneic transplantation in first complete remission.  2:1645-1650. 2018

T-cell prolymphocytic leukemia in an adolescent with ataxiatelangiectasia: Novel approach with a JAK3 inhibitor (tofacitinib).  1:2724-2728. 2017

Allogeneic bone marrow transplant in the absence of cytoreductive conditioning rescues mice with β-thalassemia major.  1:2421-2432. 2017

Mesenchymal stem cells expressing osteoprotegerin variants inhibit osteolysis in a murine model of multiple myeloma.  1:2375-2385. 2017

Recent trends in multiple myeloma incidence and survival by age, race, and ethnicity in the United States.  1:282-287. 2017

Therapeutic efficacy of the platelet glycoprotein Ib antagonist anfibatide in murine models of thrombotic thrombocytopenic purpura..  1:75-83. 2016